US 12,343,316 B2
Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases
Albert Quintana Romero, Barcelona (ES); Elisenda Sanz Iglesias, Girona (ES); and Emma Puighermanal, Barcelona (ES)
Assigned to UNIVERSITAT AUTÓNOMA DE BARCELONA, Barcelona (ES)
Appl. No. 17/310,181
Filed by UNIVERSITAT AUTONOMA DE BARCELONA, Barcelona (ES)
PCT Filed Jan. 24, 2020, PCT No. PCT/EP2020/051772
§ 371(c)(1), (2) Date Jul. 23, 2021,
PCT Pub. No. WO2020/152336, PCT Pub. Date Jul. 30, 2020.
Claims priority of application No. 19382053 (EP), filed on Jan. 25, 2019.
Prior Publication US 2022/0096395 A1, Mar. 31, 2022
Int. Cl. A61K 31/05 (2006.01); A61K 31/122 (2006.01); A61P 39/00 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 31/122 (2013.01); A61P 39/00 (2018.01)] 9 Claims
 
1. A method of treatment of Leigh syndrome (LS) comprising:
administering a compound of Formula I:

OG Complex Work Unit Chemistry
wherein:
R1 is selected from (C1-C5)alkyl, —COOH and —CH2OH; and
R2 is selected from (C5-C12)alkyl, —OR3 and —(CH2)n—O—(C1-C5)alkyl; and wherein:
R3 is selected from (C5-C9)alkyl or (C5-C9)alkyl substituted at the terminal carbon atom by a phenyl group; and
n is an integer from 1 to 7,
to a patient in need thereof.